MedTrace Logo

Radiotherapy for Prostate Cancer: Conventional Dose Versus High Dose

NCT00692107 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 669

Last updated 2008-06-06

No results posted yet for this study

Summary

3-D conformal radiotherapy offers the opportunity to reach higher tumor doses with acceptable complication rates compared to conventional radiotherapy. There are retrospective and preliminary prospective reports of a better local control / disease free survival (including PSA control) using higher tumor doses. A prospective randomised phase III study is required to validate these reports. The purpose of this randomized phase III study is to investigate and compare the tumor control and toxicity in prostate cancer patients treated to 68 Gy and 78 Gy;

Conditions

  • Prostatic Neoplasms

Interventions

RADIATION

Gray

68 Gy vs. 78 Gy

RADIATION

Gray

68 Gy vs. 78 Gy

Sponsors & Collaborators

  • Erasmus Medical Center

    collaborator OTHER

  • Dutch Cancer Society

    collaborator OTHER

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Joos V Lebesque, MD, PhD · The Netherlands Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-06-30
Primary Completion
2005-05-31
Completion
2007-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00692107 on ClinicalTrials.gov